| 1353 |
National Cancer Institute |
Html |
en |
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma |
| indolent lymphoma | 0.429154 |
| PUBMED Ab | 0.422097 |
| mediastinal B-cell lymphoma | 0.454731 |
| Low-grade MALT lymphoma | 0.426029 |
| indolent follicular lymphoma | 0.463176 |
| Engl J Med | 0.422774 |
| International Lymphoma Study | 0.450979 |
| T-cell non-Hodgkin lymphoma | 0.425991 |
| advanced-stage follicular lymphoma | 0.451924 |
| Lymphoma Study Group | 0.535602 |
| large cell lymphoma | 0.468204 |
| peripheral t-cell lymphoma | 0.456381 |
| lymphoid tissue lymphoma | 0.492221 |
| B-cell gastric lymphoma | 0.454154 |
| large b-cell lymphoma | 0.673742 |
| low-grade follicular lymphoma | 0.465805 |
| Clin Lymphoma Myeloma | 0.48896 |
| gastric MALT lymphoma | 0.456031 |
| Follicular Lymphoma International | 0.455402 |
| diffuse large b-cell | 0.567142 |
| anaplastic large-cell lymphoma | 0.485835 |
| nodal follicular lymphoma | 0.485707 |
| Follicular Lymphoma Therapy | 0.460112 |
| marginal-zone B-cell lymphoma | 0.442434 |
| et al. | 0.657474 |
|
| follicular large-cell lymphoma | 0.442424 |
| advanced-stage non-Hodgkin lymphoma | 0.443686 |
| natural killer/t-cell lymphoma | 0.443936 |
| mucosa-associated lymphoid tissue | 0.475564 |
| PUBMED Abstract | 0.461097 |
| diffuse large-B-cell lymphoma | 0.442818 |
| primary follicular lymphoma | 0.490523 |
| low-grade gastric lymphoma | 0.426685 |
| mantle cell lymphoma | 0.422703 |
| follicular lymphoma | 0.604182 |
| Abstract | 0.663115 |
| lymphoplasmacytic lymphoma | 0.440428 |
| Clin Oncol | 0.941 |
| lymphoma | 0.746021 |
| international follicular lymphoma | 0.455144 |
| Low-Grade Lymphoma Study | 0.438252 |
| non-hodgkin lymphoma | 0.449125 |
| marginal zone lymphoma | 0.509105 |
| follicular lymphoma patients | 0.482999 |
| B-Cell Lymphoma Treated | 0.458319 |
| Systemic B-Cell Lymphoma | 0.432957 |
| MALT lymphoma | 0.489467 |
| Non-Hodgkin Lymphoma Study | 0.426008 |
| Lymphoma Classification Project | 0.46454 |
|
CLICK HERE |
| 1476 |
National Cancer Institute |
Html |
en |
Adrenocortical Carcinoma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of adrenocortical carcinoma. |
| tumor marker | 0.675202 |
| out-of-phase T1-weighted imaging | 0.697012 |
| stage IV tumors | 0.659343 |
| metastatic functioning tumors | 0.801327 |
| staging tool | 0.722476 |
| PDQ cancer information | 0.856921 |
| metastatic lesions | 0.771984 |
| extracapsular tumor invasion | 0.747406 |
| staging systems | 0.691871 |
| potential lung metastasis | 0.731171 |
| adrenocortical carcinomas | 0.63434 |
| chemotherapeutic agent mitotane | 0.781817 |
| cancer information summary | 0.816255 |
| breast cancer prevention | 0.687711 |
| ENSAT staging | 0.713932 |
| mitotane antihormonal drugs | 0.805561 |
| malignant adrenal masses | 0.717902 |
| careful endocrine studies | 0.718613 |
| NCI’s PDQ | 0.665371 |
| PDQ Adult Treatment | 0.724299 |
| Proper staging | 0.693902 |
| NCI PDQ cancer | 0.764668 |
| Adrenal Tumors | 0.670042 |
| effective noninvasive method | 0.696617 |
| adrenal cancer | 0.657663 |
|
| radiation therapy | 0.69704 |
| long-term disease-free survival | 0.704486 |
| complete resection | 0.734805 |
| magnetic resonance imaging | 0.900392 |
| complete tumor resection | 0.779736 |
| excessive hormone production | 0.742148 |
| measurable tumor burden. | 0.740477 |
| steroid receptor antagonists | 0.687573 |
| hormone production | 0.798926 |
| 5-year survival | 0.724946 |
| National Cancer Institute | 0.688962 |
| le Cancer staging | 0.787658 |
| PDQ documents | 0.647653 |
| useful clinical responses | 0.679315 |
| adrenal mass. | 0.63451 |
| World Health Organization. | 0.685412 |
| measurable partial remissions | 0.680413 |
| adrenocortical carcinoma | 0.73628 |
| primary tumor | 0.750316 |
| adjuvant mitotane | 0.712566 |
| above-mentioned AJCC staging | 0.781955 |
| American Joint Committee | 0.694648 |
| regional lymph nodes | 0.695067 |
| Overall 5-year survival | 0.710773 |
|
CLICK HERE |
| 1583 |
National Cancer Institute |
Html |
null |
Childhood Liver Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of childhood liver cancer. |
|
|
CLICK HERE |
| 1809 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de pulmón de células pequeñas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de pulmón de células pequeñas. |
| Lung Cancer Cooperative | 0.40923 |
| small-cell carcinoma | 0.409726 |
| Arriagada R | 0.406258 |
| mortality from lung | 0.406031 |
| Pignon JP | 0.406568 |
| lung carcinoma | 0.415433 |
| chemotherapy with or | 0.407857 |
| thoracic irradiation | 0.411758 |
| lung cancer | 0.99158 |
| small-cell lung | 0.732567 |
| American Cancer Society | 0.407972 |
| limited-stage small-cell lung | 0.528108 |
| with once-daily thoracic | 0.405556 |
| Cancer Data Base | 0.408315 |
| tobacco-specific lung carcinogen | 0.40968 |
| Lung Oncology Group | 0.405386 |
| Radiat Oncol Biol | 0.407067 |
| Lung Cancer Group | 0.40944 |
| oncology group study | 0.409486 |
| Natl Cancer Inst | 0.413727 |
| Council Lung Cancer | 0.408713 |
| patients with | 0.422455 |
| cancer lung | 0.415587 |
| Does thoracic irradiation | 0.406837 |
| small cell carcinoma | 0.40583 |
|
| small-cell lung carcinoma | 0.412738 |
| childhood cancer | 0.406909 |
| with small-cell lung | 0.428402 |
| Lung Cancer Working | 0.414426 |
| National Cancer | 0.425705 |
| extensive small-cell lung | 0.412452 |
| Clinical Trials Group | 0.406926 |
| small cell lung | 0.507254 |
| National Cancer Institute | 0.418442 |
| prophylactic cranial irradiation | 0.410926 |
| combination chemotherapy with | 0.405558 |
| with combination chemotherapy | 0.405558 |
| National Cancer Data | 0.408383 |
| Clin Oncol | 0.533689 |
| Oncol Biol Phys | 0.407177 |
| combined modality treatment | 0.409248 |
| Low-dose lung | 0.405724 |
| Canada Clinical Trials | 0.406735 |
| treated with | 0.408022 |
| Cancer Working Party | 0.407006 |
| with or without | 0.405778 |
| lung tumours | 0.405564 |
| Cancer Survivor Study | 0.405383 |
| thoracic radiotherapy | 0.433304 |
|
CLICK HERE |
| 1828 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia linfoblástica aguda en adultos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda en adultos. |
| Italy Leukemia Group | 0.510748 |
| prognostic factors | 0.523487 |
| in adults | 0.649162 |
| tirosina cinasa bcr-abl | 0.513926 |
| largo plazo | 0.507147 |
| leukemia group | 0.574628 |
| or fab l3 | 0.5087 |
| LLA Ph1 | 0.523666 |
| chronic myeloid leukemia | 0.519002 |
| Thiel E | 0.520173 |
| TMO autógeno | 0.523146 |
| adults with | 0.569541 |
| leucemia mielógena | 0.512104 |
| donante fraterno | 0.513552 |
| lymphocytic leukemia | 0.529118 |
| Löffler H | 0.510187 |
| LLA recién | 0.516678 |
| induction regimen with | 0.509327 |
| in adults with | 0.545834 |
| patients with | 0.533511 |
| complete remission | 0.509903 |
| leucemia mielocÃtica aguda | 0.512148 |
| multicenter study | 0.514475 |
| adults with standard-risk | 0.510496 |
| myeloid leukemia | 0.519806 |
|
| marrow transplantation | 0.523773 |
| leucemia aguda | 0.509415 |
| leucemia linfoblástica aguda | 0.65786 |
| TMO alogénico | 0.56508 |
| bone marrow transplantation | 0.52273 |
| morfologÃa l3 | 0.522238 |
| Hoelzer D | 0.525554 |
| leukemia with | 0.523655 |
| Adult Leukemia Study | 0.507091 |
| Northern Italy Leukemia | 0.510296 |
| Horowitz MM | 0.508541 |
| LLA L3 | 0.549875 |
| International ALL Trial | 0.508909 |
| PDQ Tratamiento | 0.509128 |
| Dodge RK | 0.508725 |
| Brief-duration high-intensity chemotherapy | 0.50796 |
| bone marrow transplant | 0.513671 |
| Clin Oncol | 0.534506 |
| sistema nervioso central | 0.584696 |
| bone marrow | 0.527725 |
| with small noncleaved-cell | 0.509543 |
| acute lymphoblastic leukemia | 0.981898 |
| leukemia with hyper-CVAD | 0.507761 |
| lla recidivante quimioterapia | 0.519565 |
|
CLICK HERE |
| 1966 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de labio y de cavidad oral (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de labio y de cavidad oral. |
| medicamentos retinoides | 0.568081 |
| siguientes procedimientos | 0.97932 |
| siguientes elementos | 0.624752 |
| estadio ii | 0.723086 |
| rayos x | 0.572217 |
| pequeñas marcas | 0.537003 |
| estadio ivc | 0.583451 |
| necesarios implantes | 0.546577 |
| siguientes riesgos | 0.500736 |
| malla ayuda | 0.53799 |
| Instituto Nacional | 0.536147 |
| área pequeña detrás | 0.642422 |
| presente sección | 0.536306 |
|
| partes distantes | 0.555475 |
| Physician Data Query | 0.531283 |
| estadio iii | 0.581263 |
| libre uso | 0.500877 |
| radioterapia hiperfraccionada | 0.899395 |
| cáncer.ampliar radioterapia | 0.670655 |
| Cancer Institute | 0.499502 |
| siguientes enlaces | 0.516515 |
| siguientes pruebas | 0.617318 |
| Dientes flojos | 0.587562 |
| pequeño espejo | 0.576408 |
| siguientes estadios | 0.58645 |
|
CLICK HERE |
| 2061 |
National Cancer Institute |
Html |
es |
Mamografías |
Hoja informativa que define las mamografías de detección y de diagnóstico; trata de los beneficios y perjuicios posibles de las mamografías de detección; y resume cómo se reportan los resultados, incluso la densidad de los senos. |
| largo perÃodo | 0.329403 |
| federal affordable care | 0.358034 |
| mamografÃa digital | 0.901811 |
| Database System | 0.32976 |
| de estudios clÃnicos aleatorizados y | 0.369135 |
| técnica especial llamada | 0.347452 |
| programa brinda servicios | 0.346724 |
| posibles limitaciones | 0.337532 |
| rayos x | 0.327782 |
| breast self-exam | 0.336335 |
| CategorÃa Evaluación Seguimiento | 0.350863 |
| posibles perjuicios | 0.338669 |
| alta densidad | 0.339314 |
| tratamiento. Las mamografÃas | 0.58289 |
| pequeñas masas | 0.327877 |
| Exposición a radiación. Las mamografÃas | 0.580742 |
| Resultado benigno | 0.343535 |
| Breast Imaging Reporting | 0.356725 |
| pequeños depósitos de calcio | 0.365542 |
| Colegio Estadounidense | 0.332034 |
| seguro médico | 0.544063 |
|
| mujeres con implantes | 0.382313 |
| detección temprana | 0.693756 |
| Healthcare Research | 0.333438 |
| al feto en crecimiento | 0.333178 |
| casos de carcinoma | 0.332936 |
| Instituto Nacional | 0.371979 |
| Mammography Quality Standards | 0.352873 |
| mujer nota | 0.33784 |
| normales aun | 0.335316 |
| tanta rapidez | 0.335356 |
| usa luz | 0.328978 |
| 3D usa dosis | 0.354905 |
| Requiere biopsia | 0.343563 |
| Estados Unidos | 0.809815 |
| pequeñas de radiación | 0.330854 |
| Cuello Uterino | 0.329522 |
| posibles beneficios | 0.33135 |
| positivos falsos. Los resultados | 0.376938 |
| ley mqsa | 0.332395 |
| decisiones médicas que | 0.334533 |
| mujeres jóvenes | 0.457334 |
|
CLICK HERE |
| 3429 |
National Cancer Institute |
Html |
es |
Agua fluorada |
Hoja informativa que examina los estudios realizados sobre la posible conexión entre el agua fluorada y el cáncer. |
| Villanacci JF | 0.447057 |
| Feltbower RG | 0.446597 |
| fluoruro ingerido | 0.954566 |
| Mortality Weekly Report | 0.483586 |
| vasta cantidad | 0.449716 |
| carcinogenicity studies with | 0.478781 |
| bajas. Muchos estudios | 0.468962 |
| Water Fluoridation Statistics | 0.487645 |
| Toxicology Program rodent | 0.480514 |
| Napier TS | 0.445775 |
| Ewing sarcoma diagnosed | 0.483942 |
| Great Britain | 0.443018 |
| Disease Control | 0.536557 |
| public drinking water | 0.505168 |
| National Academy | 0.558901 |
| Instituto Nacional | 0.520062 |
| agua ayuda | 0.629089 |
| Environmental Health | 0.58081 |
| Related Programs | 0.449277 |
| Estados Unidos | 0.666074 |
| Kim FM | 0.441491 |
| resultados contradictorios | 0.444365 |
| Ingested Fluoride | 0.54922 |
| PubMed Abstract | 0.93552 |
|
| among 0-49-year-olds | 0.445423 |
| Williams PL | 0.44275 |
| salud pública | 0.65032 |
| Ad Hoc Subcommittee | 0.477798 |
| International Journal | 0.533052 |
| Blakey K | 0.445319 |
| Dental Research | 0.46834 |
| Parslow RC | 0.444263 |
| Health Effects | 0.572713 |
| Grand Rapids | 0.447598 |
| Hejtmancik MR | 0.446466 |
| Environmental Health Sciences | 0.528481 |
| Hayes C | 0.441487 |
| Toft JD | 0.447997 |
| drinking water | 0.564502 |
| public health | 0.755217 |
| National Institute | 0.45889 |
| Coordinate Environmental Health | 0.506784 |
| prevent dental caries | 0.542747 |
| Retrieved August | 0.565765 |
| Salud Ambiental | 0.441563 |
| National Research Council | 0.675505 |
| siglo xx | 0.446805 |
| Public Health Service | 0.715782 |
|
CLICK HERE |
| 3604 |
National Cancer Institute |
Html |
null |
Advancing Precision Medicine in Oncology |
Multiyear funding for the Precision Medicine Initiative® (PMI) will help accelerate progress toward the promising new era of precision medicine in oncology. |
|
|
CLICK HERE |
| 15649 |
National Cancer Institute |
Html |
en |
Genomic Data Sharing (GDS) Policy |
The NIH Genomic Data Sharing (GDS) Policy was issued to promote broad sharing of genomic research data and ensure oversight and protections for research involving human data. |
| Policy | 0.279904 |
| GDS | 0.601385 |
|
| National Cancer Institute | 0.917963 |
| Genomic Data | 0.846899 |
|
CLICK HERE |